At elucidating


As the first FDA-approved long-term VTE prevention, it is most likely that Bevyxxa will eventually generate blockbuster sales.We expect sales to increase drastically by year-end and to catapult to new highs in early 2019.Advantages of NOACs include the followings: faster onset of action, shorter half-life (less adverse effects, bleeding), fewer drugs interaction, dosing stability, and without the need for daily monitoring of the International Normalized Ratio (“INR”).As the quantitative metric of how thin the blood is, INR monitoring can be cumbersome for physicians.In the middle of difficulty lies the great opportunity: the negative regulatory catalyst, as mentioned, created a rare entry for those who have yet to purchase shares of Portola.There are many reasons to be bullish on the company as we featured in our four parts analytical research: I, II, III, and IV.

We stated in our prior article, The oral VKA (warfarin) is commonly used to prevent blood clots in the artery of the heart and brain of patients with heart diseases (i.e.The negative regulatory catalyst from the EU serves as an excellent entry point for those who have yet to purchase this highly promising grower.In the past 5-days, the shares of Portola Pharmaceuticals (NASDAQ: PTLA), a bioscience firm specializing in the innovation and commercialization of medicines to treat blood disorders and cancers, traded .57 lower (-25%) at .25.Nevertheless, the bullish trading sent the stock 8% higher today.Of note, the aforesaid pessimism is due to the negative regulatory catalyst from the EMA pertaining to the FDA-approved molecule, Bevyxxa (as well as the request for additional data on Andex Xa by the FDA).As a novel oral anticoagulant (“NOAC”), betrixaban (Bevyxxa) was FDA approved as the long-term prophylaxis for venous thromboembolism (“VTE”) in adult patients on June 23, 2017.

You must have an account to comment. Please register or login here!